AbbVie lutikizumab meets primary endpoint in Phase 3, but efficacy below market bar

AbbVie's lutikizumab succeeded in a late-stage trial for a chronic skin condition, meeting its primary endpoint. However, the magnitude of efficacy fell short of market expectations, likely tempering commercial prospects. The miss may pressure AbbVie's stock and raise questions about the drug's differentiation in a competitive dermatology market.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works